Beth Seidenberg, MD, is a founding managing director of Westlake Village BioPartners and a partner at Kleiner Perkins, a leading venture capital firm. A longtime life sciences investor, she has incubated-invested more than 20 biotech ventures.
Dr. Seidenberg has a demonstrated ability to identify and accelerate medically meaningful molecules through development. Her expertise is grounded in her significant senior level industry experience with leadership roles at Amgen, Bristol-Myers Squibb and Merck Research Laboratories. Most recently, at Amgen, Dr. Seidenberg was Chief Medical Officer and Head of Global Development.
Prior to life science investing, Dr. Seidenberg’s career focused on developing new treatments for AIDS, arthritis, asthma, cancer and psoriasis, cardiovascular, metabolic, neurological and renal disorders for over 20 years. During that time, she introduced 10 innovative products to market and achieved over 40 regulatory approvals (including new indications and formulations) on a worldwide scale.
Dr. Seidenberg holds a Bachelor of Science degree in biology and anthropology from Barnard College and attended medical school at the University of Miami School of Medicine. She completed her medical residency at Johns Hopkins University and the George Washington University, and Fellowship at the National Institutes of Health.
What is Beth C. Seidenberg's net worth?
The estimated net worth of Beth C. Seidenberg is at least $8.63 million as of December 18th, 2025. Dr. Seidenberg owns 869,317 shares of Kyverna Therapeutics stock worth more than $8,632,318 as of April 17th. This net worth estimate does not reflect any other investments that Dr. Seidenberg may own. Learn More about Beth C. Seidenberg's net worth.
How do I contact Beth C. Seidenberg?
Has Beth C. Seidenberg been buying or selling shares of Kyverna Therapeutics?
Beth C. Seidenberg has not been actively trading shares of Kyverna Therapeutics during the last ninety days. Most recently, on Thursday, December 18th, Beth C. Seidenberg bought 133,333 shares of Kyverna Therapeutics stock. The stock was acquired at an average cost of $7.50 per share, with a total value of $999,997.50. Following the completion of the transaction, the director now directly owns 869,317 shares of the company's stock, valued at $6,519,877.50. Learn More on Beth C. Seidenberg's trading history.
Are insiders buying or selling shares of Kyverna Therapeutics?
During the last twelve months, Kyverna Therapeutics insiders bought shares 2 times. They purchased a total of 266,666 shares worth more than $1,999,995.00. During the last twelve months, insiders at the sold shares 1 times. They sold a total of 23,998 shares worth more than $292,775.60. The most recent insider tranaction occured on December, 18th when Director Beth C Seidenberg bought 133,333 shares worth more than $999,997.50. Insiders at Kyverna Therapeutics own 22.0% of the company.
Learn More about insider trades at Kyverna Therapeutics. Information on this page was last updated on 12/18/2025.
